A New Role for ERα: Silencing via DNA Methylation of Basal, Stem Cell, and EMT Genes

Area of Science:

• Oncology
• Epigenetics
• Molecular Biology

Background:

• Hormonal therapy resistance is a significant challenge in treating estrogen receptor alpha-positive (ERα+) breast cancer.
• Epigenetic modifications, specifically DNA methylation (5mCpG), are linked to ERα+ status in breast cancers.
• ERα may control gene expression partly through DNA methylation.

Purpose of the Study:

• To investigate the hypothesis that ERα regulates gene expression via DNA methylation.
• To identify genes regulated by ERα-dependent DNA methylation in breast cancer models.
• To assess the potential of these genes as predictive biomarkers for breast cancer patient outcomes.

Main Methods:

• Utilized breast cancer cell line models resistant to antiestrogen therapy.
• Employed microarray gene expression profiling to identify differentially methylated genes.
• Analyzed ERα-binding sites, gene expression patterns, and patient survival data.

Main Results:

• Identified 39 ERα-dependent DNA methylation targets enriched for ERα-binding sites, basal/luminal markers, cancer stem cell, EMT, inflammatory, and tumor suppressor genes.
• These targets were associated with poor distant metastasis-free survival in a large breast cancer patient cohort.
• Basal breast cancer markers LCN2 and IFI27 demonstrated an inverse relationship with ERα activity and contained ERα-binding sites.

Conclusions:

• ERα actively directs DNA methylation to silence specific genes in breast cancer.
• ERα-regulated methylated genes hold potential as predictive biomarkers for breast cancer subtypes.
• Understanding ERα-mediated DNA methylation could offer new therapeutic strategies and improve patient stratification.